Log in

NASDAQ:DVAX - Dynavax Technologies Stock Price, Forecast & News

$5.18
-0.04 (-0.77 %)
(As of 02/17/2020 02:47 AM ET)
Add
Today's Range
$5.06
Now: $5.18
$5.22
50-Day Range
$4.99
MA: $5.56
$6.20
52-Week Range
$2.60
Now: $5.18
$11.44
Volume706,375 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:DVAX
CUSIP26815810
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees249
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive DVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.


Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) released its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.10. The biopharmaceutical company had revenue of $10.58 million for the quarter, compared to analysts' expectations of $10.31 million. The company's quarterly revenue was up 624.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.65) earnings per share. View Dynavax Technologies' Earnings History.

When is Dynavax Technologies' next earnings date?

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Dynavax Technologies.

What price target have analysts set for DVAX?

5 brokerages have issued 12 month target prices for Dynavax Technologies' stock. Their forecasts range from $13.00 to $20.00. On average, they expect Dynavax Technologies' share price to reach $15.33 in the next year. This suggests a possible upside of 196.0% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.

What is the consensus analysts' recommendation for Dynavax Technologies?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.

Has Dynavax Technologies been receiving favorable news coverage?

News stories about DVAX stock have trended somewhat positive on Monday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dynavax Technologies earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Dynavax Technologies.

Who are some of Dynavax Technologies' key competitors?

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Array Biopharma (ARRY), United Continental (UAL), Kite Pharma (KITE), Cara Therapeutics (CARA) and Micron Technology (MU).

Who are Dynavax Technologies' key executives?

Dynavax Technologies' management team includes the folowing people:
  • Mr. Eddie Gray, CEO & Director (Age 60)
  • Dr. Dennis A. Carson Ph.D., M.D., Co-Founder, Director & Member of Scientific Advisory Board (Age 72)
  • Mr. Michael S. Ostrach, CFO, Chief Bus. Officer & Sr. VP (Age 67)
  • Mr. David F. Novack, Sr. VP of Operations & Quality (Age 57)
  • Dr. Robert L. Coffman, Chief Scientific Officer & Sr. VP (Age 72)

Who are Dynavax Technologies' major shareholders?

Dynavax Technologies' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Chicago Capital LLC (4.77%), Senvest Management LLC (4.76%), Bain Capital Public Equity Management II LLC (4.24%), State Street Corp (4.11%), UBS Asset Management Americas Inc. (2.08%) and Blair William & Co. IL (2.01%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Institutional Ownership Trends for Dynavax Technologies.

Which major investors are selling Dynavax Technologies stock?

DVAX stock was sold by a variety of institutional investors in the last quarter, including Senvest Management LLC, Point72 Asset Management L.P., Chicago Capital LLC, FMR LLC, DekaBank Deutsche Girozentrale, Rhenman & Partners Asset Management AB, Bank of America Corp DE and Gables Capital Management Inc.. Company insiders that have sold Dynavax Technologies company stock in the last year include David Louis Johnson, Michael S Ostrach and Robert Coffman. View Insider Buying and Selling for Dynavax Technologies.

Which major investors are buying Dynavax Technologies stock?

DVAX stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Bain Capital Public Equity Management II LLC, Oxford Asset Management LLP, Rafferty Asset Management LLC, California Public Employees Retirement System, Alpine Global Management LLC, Blair William & Co. IL and Bank of New York Mellon Corp. View Insider Buying and Selling for Dynavax Technologies.

How do I buy shares of Dynavax Technologies?

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Dynavax Technologies' stock price today?

One share of DVAX stock can currently be purchased for approximately $5.18.


MarketBeat Community Rating for Dynavax Technologies (NASDAQ DVAX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  401 (Vote Outperform)
Underperform Votes:  403 (Vote Underperform)
Total Votes:  804
MarketBeat's community ratings are surveys of what our community members think about Dynavax Technologies and other stocks. Vote "Outperform" if you believe DVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: Cost of Goods Sold (COGS)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel